Nutriband Inc. (NASDAQ: NTRB, NTRBW), a company specializing in the development of prescription transdermal pharmaceutical products, has announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This move aims to bolster the intellectual property protection for its AVERSA™ abuse-deterrent transdermal technology, which is designed to address the misuse and abuse of drugs with high abuse potential, such as opioids and stimulants.
The AVERSA™ technology employs a proprietary aversive agent coating that uses taste aversion to deter oral abuse and reduce accidental exposure. The newly filed provisional patent application focuses on improved aversive formulations and advanced coating application methods, further enhancing the abuse-deterrent properties of the technology. If converted into a non-provisional patent application and subsequently granted, this patent could significantly extend the protection of products utilizing AVERSA™, as U.S. patents have a statutory term of 20 years from the non-provisional filing date.
Nutriband’s AVERSA™ technology is already protected by an extensive international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia. This global reach underscores the company’s commitment to safeguarding its innovative solutions and ensuring their availability to patients worldwide.
The AVERSA™ abuse-deterrent technology is designed to incorporate aversive agents into transdermal patches, making it more difficult to misuse or abuse drugs with high abuse potential. This includes opioids and stimulants, which are often subject to diversion, misuse, and accidental exposure. By improving the safety profile of these drugs, AVERSA™ technology ensures that they remain accessible to patients who genuinely need them, while reducing the risks associated with their use.
About AVERSA™ Abuse-Deterrent Technology
AVERSA™ technology represents a significant advancement in the field of transdermal drug delivery. By integrating aversive agents into transdermal patches, the technology deters abuse, misuse, and accidental exposure. This innovation is particularly critical for drugs like opioids and stimulants, which are prone to abuse. The technology’s broad patent coverage across multiple countries highlights its global potential to address a pressing public health issue.
About Nutriband Inc.
Nutriband Inc. is at the forefront of developing transdermal pharmaceutical products, with a focus on improving drug safety and accessibility. The company’s flagship product under development is an abuse-deterrent fentanyl patch that incorporates AVERSA™ technology. This groundbreaking technology can be applied to any transdermal patch, providing a versatile solution to prevent the misuse and abuse of drugs with high abuse potential.
For more information, visit the company’s website at www.nutriband.com. Please note that any material contained on the company’s website or other websites is not considered part of this press release.
The post Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse-Deterrent Technology appeared first on PRISM MarketView.
